Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
680.7 INR | +0.60% | +2.26% | +24.73% |
04-25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
04-17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Sales 2022 | 61.3B 735M 58.87B | Sales 2023 | 62.82B 753M 60.33B | Capitalization | 44.42B 533M 42.66B |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.64M 3.97B | Net income 2023 | -610M -7.32M -586M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M 21.15B | Net Debt 2023 | 26.44B 317M 25.39B | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +0.60% | ||
1 week | +2.26% | ||
Current month | +19.74% | ||
1 month | +19.09% | ||
3 months | +19.74% | ||
6 months | +71.83% | ||
Current year | +24.73% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 22/05/17 | |
Chief Executive Officer | 37 | 22/05/17 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 31/03/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 31/12/81 | |
Chairman | 71 | 20/06/78 | |
Chief Executive Officer | 46 | 22/05/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.14% | - | |
0.00% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 680.7 | +0.60% | 13,544 |
25/04/24 | 676.6 | -0.86% | 24,536 |
24/04/24 | 682.6 | -0.31% | 10,440 |
23/04/24 | 684.7 | +0.51% | 30,129 |
22/04/24 | 681.2 | +2.34% | 52,445 |
Delayed Quote Bombay S.E., April 26, 2024 at 11:00 am
More quotes1st Jan change | Capi. | |
---|---|---|
+24.73% | 1.3B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JUBLPHARMA Stock